Skip to main content

Table 2 Proportion of participants who quit smoking (biochemically confirmed and self-reported) and proportion who reduced the number of cigarettes smoked per day

From: Randomised controlled trial testing effectiveness of feedback about lung age or exhaled CO combined with very brief advice for smoking cessation compared to very brief advice alone in North Macedonia: findings from the Breathe Well group

 

VBA only

VBA + lung age

VBA + exhaled CO

VBA + lung age

VBA + exhaled CO

Total

n (%)

Total

n (%)

Total

n (%)

RR (95% CI)

p-value

RR (95% CI)

p-value

Quit smoking (biochemically confirmed)

 At 4wksa

450

8 (1.8)

449

7 (1.6)

442

8 (1.8)

0.90 (0.35–2.27)b

0.792

1.04 (0.44–2.44)b

0.920

 At 12wks

445

8 (1.8)

447

6 (1.3)

440

10 (2.3)

0.78 (0.32–1.89)

0.578

1.29 (0.65–2.57)

0.463

 At 26wks

435

1 (0.2)

438

7 (1.6)

428

3 (0.7)

6.98 (1.09–44.54)

0.040

3.11 (0.28–35.10)

0.358

Quit smoking (self-reported)

 At 4wks

450

8 (1.8)

449

9 (2.0)

442

15 (3.4)

1.15 (0.51–2.59)

0.731

1.95 (0.92–4.10)

0.080

 At 12wks

445

11 (2.4)

447

11 (2.4)

439

18 (4.1)

1.02 (0.45–2.30)

0.970

1.69 (0.73–3.91)

0.218

 At 26wks

435

11 (2.5)

437

17 (3.9)

428

15 (3.5)

1.58 (0.74–3.38)

0.243

1.41 (0.65–3.08)

0.391

Reduction in cpd

 At 4wks

389

110 (28.3)

386

141 (36.5)

383

132 (34.5)

1.30 (1.10–1.54)

0.002

1.23 (1.03–1.49)

0.026

 At 12wks

385

143 (37.1)

380

160 (42.1)

376

152 (40.4)

1.15 (1.00–1.32)

0.048

1.11 (0.93–1.32)

0.240

 At 26wks

372

172 (46.2)

365

173 (47.4)

366

182 (49.7)

1.03 (0.94–1.14)

0.507

1.09 (0.95–1.26)

0.225

  1. All analyses adjusted for primary care research site as a random effect
  2. RR Relative Risk, compared with VBA only, cpd Cigarettes smoked per day
  3. aPrimary outcome: Proportion of smokers who are quit at 4 weeks (7-day point prevalence self-reported abstinence), confirmed with salivary cotinine level of: (1) < 10ng/ml, or (2) < 100ng/ml for those who report SHS exposure in the home on a daily basis, or (3) ≥ 10ng/ml in those who report using NRT/e-cigarettes at any time point during the study, irrespective of second-hand smoke exposure
  4. bConfidence interval for primary outcome is 97.5%